Cargando…
Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
COPD is characterized by progressive airflow obstruction which does not fully reverse to inhaled or oral pharmacotherapy. The management of patients with COPD has taken a totally new direction over the past 20 years, thank to the use of novel therapies aimed to improve and modify the natural history...
Autores principales: | Rossi, Andrea, Khirani, Sonia, Cazzola, Mario |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650610/ https://www.ncbi.nlm.nih.gov/pubmed/19281071 |
Ejemplares similares
-
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
por: Sion, Katya Y. J., et al.
Publicado: (2017) -
Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015) -
Efficacy and safety of revefenacin for nebulization in patients with
chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA:
subgroup analysis from phase III trials
por: Sethi, Sanjay, et al.
Publicado: (2020) -
The safety of long-acting β(2)-agonists in the treatment of stable chronic obstructive pulmonary disease
por: Decramer, Marc L, et al.
Publicado: (2013) -
Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
por: Burkes, Robert M, et al.
Publicado: (2020)